Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

Inclusion Criteria

• •1. Patient is ≥ 18 years of age.
• •2. r/r PCNSL patient, who has newly started NHI public reimbursement tirabrutinib from 01 June 2024 to 30 June 2025.
• •3. Have provided voluntary written consent, directly from the subject, or through his/her legal representative for a patient who has died or lacks the capacity to give informed consent
• •Note: The NHI reimbursement criteria are listed below for reference purposes only. Subject enrollment depends on whether reimbursement has been received.
• •1. Histopathologically confirmed large B-cell PCNSL.
• •2. Patients with relapsed or refractory PCNSL previously treated at least 2 cycles of HD-MTX.
• •3. Exclude HIV infection
• •4. Exclude Burkitt lymphoma
• •5. Exclude patients using chemotherapy or monoclonal antibodies at the initiation of tirabrutinib treatment.